NCT01549730View on ClinicalTrials.gov

Cervix Hypoxia FAZA

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Cervix Cancer
Interventions
PROCEDURE

18F-Fluoroazomycin Arabinoside (18F-FAZA)

A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER